Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $14.6 million.

  • Anika Therapeutics' Shares Outstanding (Weighted Average) fell 2.56% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 2.56%. This contributed to the annual value of $14.6 million for FY2024, which is 0.03% up from last year.
  • Anika Therapeutics' Shares Outstanding (Weighted Average) amounted to $14.6 million in FY2024, which was up 0.03% from $14.6 million recorded in FY2023.
  • Over the past 5 years, Anika Therapeutics' Shares Outstanding (Weighted Average) peaked at $14.6 million during FY2024, and registered a low of $14.2 million during FY2020.
  • For the 3-year period, Anika Therapeutics' Shares Outstanding (Weighted Average) averaged around $14.6 million, with its median value being $14.6 million (2023).
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first decreased by 0.38% in 2020, then increased by 1.56% in 2021.
  • Anika Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $14.2 million in 2020, then increased by 1.56% to $14.4 million in 2021, then climbed by 1.20% to $14.6 million in 2022, then increased by 0.21% to $14.6 million in 2023, then increased by 0.03% to $14.6 million in 2024.